The Global Market for Intravenous Immunoglobulin (IVIg) is Projected to Reach US$15.9 Billion by 2024
Rising Incidence of Immune Disorders Drive the Intravenous
Immunoglobulin (IVIg) Market, According to a New Report by Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry segments, trends, growth drivers, market size, share and
demand forecasts on the global Intravenous Immunoglobulin (IVIg) market. The global market for Intravenous Immunoglobulin
(IVIg) is projected to reach US$15.9 billion by 2024, driven by aging population, increasing incidence of
autoimmune diseases such as lupus, growing awareness and rising adoption in
emerging markets.
Immunoglobulins or
antibodies are naturally occurring human blood constituents that when extracted
and concentrated find use in the treatment of various diseases related to
immune deficiency. Intravenous Immunoglobulin (IVIg) contains pooled
immunoglobulin/antibody G that is administered intravenously for the treatment
of various immune deficiencies. Currently, IVIg is the most important blood
plasma protein therapy used in the treatment of a variety of labeled and
unlabeled indications across therapeutic areas such as neurology, hematology
and immunology. Growing geriatric population, increasing incidence and
prevalence of various target conditions, rising awareness, supportive
reimbursements, growing approved and off-label use and increasing healthcare
expenditure are some of the major factors driving market growth. Expansion of
indications over the years and rise in off-label use are other factors
contributing to rise in demand for IVIg.
Primary Immunodeficiency (PI) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are the major indications for IVIg. All IVIg products
available on the market are indicated for PI. Increasing efforts to improve
identification of PI patients through building awareness and diagnostics in
markets such as the US and UK, while growing awareness in emerging markets are
expected to further boost adoption of IVIg. Certain existing intravenous
products are currently undergoing life-cycle management as they are being
tested for new indications and new markets, including CIDP. Further, efforts
are underway to test the efficacy of IVIg therapy in the treatment of
Alzheimer’s – an area of significant unmet needs. Expansion of indications is
expected to offer further ground for market penetration and thereby fuel market
growth. Stringent governmental regulations related to appropriate usage of
IVIg, high treatment costs, and high risks of side-effects are some of factors
restraining market growth.
As stated by the new
market research report on Intravenous Immunoglobulin (IVIg), The U.S. represents the largest market worldwide for
Intravenous Immunoglobulin (IVIg). High demand in the country is driven by
large target patient population, rising geriatric population, high level of
awareness and favorable government policies, higher overall awareness, presence
of advanced medications and better reimbursement environment. Asia-Pacific represents
the fastest growing market worldwide, with a CAGR of 9.7% through the analysis
period. Growing geriatric population, improving healthcare infrastructure,
rising incomes and increasing purchasing power are driving demand for IVIg in
the region.
Major players in the market
include Bharat Serums and Vaccines Limited, Biotest AG, China Biologic
Products, Inc., Guizhou Taibang Biological Products Co., Ltd., CSL Limited,
Grifols, S.A., Hualan Biological Engineering Inc., Kedrion S.p.A., LFB Group,
Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Shire plc and Sichuan
Yuanda Shuyang Pharmaceutical Co., Ltd. among others.
The research report titled
“Intravenous Immunoglobulin (IVIg): A Global Strategic
Business Report” announced by Global
Industry Analysts Inc., provides a comprehensive
review of market trends, issues, drivers, mergers, acquisitions and other
strategic industry activities of global companies. The report provides market
estimates and projections for Intravenous Immunoglobulin (IVIg) in value terms
for all major geographic markets such as United States, Canada, Japan, Europe
(France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific (Australia,
China and Rest of Asia-Pacific) and Rest of World. The report also analyzes the
market for IVIg in volume terms for the following geographical markets: United
States, Canada, Japan, Europe, Asia-Pacific and Rest of World.
Global
Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights
Reserved.
Comments
Post a Comment